用于骨髓增殖性肿瘤风险分层的动脉与静脉血栓形成临床分子评分
该研究在大型长期随访的骨髓增殖性肿瘤(MPN)队列中描绘血栓形成全景,多变量分析确定既往动脉血栓、年龄>60岁、心血管危险因素及TET2或DNMT3A突变为动脉血栓独立相关因素,据此构建的ARTS评分区分低危(0.37%患者年)与高危(1.19%患者年)患者,性能优于传统两层风险分层;静脉血栓评分VETS区分能力差,需进一步改进。
要点
- ARTS评分基于既往动脉血栓、年龄>60岁、心血管危险因素及TET2或DNMT3A突变,区分低危0.37%患者年与高危1.19%患者年。
- ARTS在训练队列所有MPN亚型及两个外部验证队列中性能优于传统两层风险分层。
- VETS评分基于既往静脉血栓及JAK2V617F变异等位基因频率≥50%,区分能力差,与传统两层风险分层相似。
核心结论
- 研究揭示MPN相关动脉与静脉血栓形成的临床分子差异,并提出ARTS评分以更准确地进行患者分层。
- 静脉血栓风险评分需纳入更多因素并考虑静脉血栓为异质性实体以进一步改进。
研究设计与样本
- 研究类型为在大型长期随访MPN队列中进行的观察性分析,包括训练队列及两个外部验证队列。
主要发现
- 多变量分析显示,既往动脉血栓、年龄>60岁、心血管危险因素及TET2或DNMT3A突变与动脉血栓独立相关。
- ARTS评分定义低危(0.37%患者年)和高危(1.19%患者年)患者,其性能在训练队列所有MPN亚型及两个外部验证队列中优于传统两层风险分层。
- 既往静脉血栓和JAK2V617F突变伴变异等位基因频率≥50%与静脉血栓独立相关。
- VETS评分的区分能力差,与传统两层风险分层相似。
关键数值与推荐
- ARTS评分低危组血栓发生率为0.37%患者年,高危组为1.19%患者年。
- VETS评分基于既往静脉血栓和JAK2V617F变异等位基因频率≥50%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文指出需进一步改进静脉风险评分,纳入额外因素并考虑静脉血栓为异质性实体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current recommended risk scores to predict thrombotic events associated with myeloproliferative neoplasms (MPN) do not discriminate between arterial and venous thrombosis despite their different physiopathology. To define novel stratification systems, we delineated a comprehensive landscape of MPN associated thrombosis across a large long-term follow-up MPN cohort. Prior arterial thrombosis, age >60 years, cardiovascular risk factors and presence of TET2 or DNMT3A mutations were independently associated with arterial thrombosis in multivariable analysis. ARTS, an ARterial Thrombosis Score, based on these four factors, defined low- (0.37% patients-year) and high-risk (1.19% patients-year) patients. ARTS performance was superior to the two-tiered conventional risk stratification in our training cohort, across all MPN subtypes, as well as in two external validation cohorts. Prior venous thrombosis and presence of a JAK2V617F mutation with a variant allelic frequency ≥50% were independently associated with venous thrombosis. The discrimination potential of VETS, a VEnous Thrombosis Score based on these two factors, was poor, similar to the two-tiered conventional risk stratification. Our study pinpoints arterial and venous thrombosis clinico-molecular differences and proposes an arterial risk score for more accurate patients' stratification. Further improvement of venous risk scores, accounting for additional factors and considering venous thrombosis as a heterogeneous entity is warranted.
引用
- Pasquer H, Daltro de Oliveira R, Vasseur L, et al. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia. 2023. PMID: 38148396. doi:10.1038/s41375-023-02114-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。